AIM ImmunoTech, Inc. (AIM) - Gross Profit Rate

AIM ImmunoTech develops advanced treatments to combat oncology and viruses, overcoming complexities in the registration of its lead drug candidate. Gross margin profitability reflects profit dynamics after production costs, where the -945.00 mark characterizes this parameter. Business stability is ensured through long-term capacity reservations with US contract packaging partners.
Comprehensive metric breakdowns and analytics for AIM ImmunoTech, Inc. (AIM)

Scaling the Ampligen drug within oncology requires high cost-efficiency, making gross margin a key indicator of operational performance for AIM ImmunoTech (AIM). This metric is calculated as the portion of revenue minus direct production costs, determining the business's ability to generate profit before accounting for administrative expenses. Analyzing gross profit margin trends allows investors to assess the sustainability of the business model and avoid overpaying for the asset.